Evidence map›Paper›PMID 42418253›Full record

ArticleJournal of medical Internet research2026

Large Language Models for World Health Organization-Uppsala Monitoring Centre Drug-Adverse Event Causality Assessment Using Food and Drug Administration Adverse Event Reporting System Cases: Comparative Performance Study.

Young Mi Ha, Minjung Kim, YoungIn Bang, Daejin Choi, Jae Hyun Kim, Sandy Jeong Rhie, Yoshihiro Noguchi, Myeong Gyu Kim

Abstract readComparative Study
In one paragraph

Article in Journal of medical Internet research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Young Mi HaGraduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.ORCID https://orcid.org/0009-0003-1772-331X
Minjung KimGraduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-8718-8469
YoungIn BangCollege of Pharmacy, Ewha Womans University, Seoul, Republic of Korea.ORCID https://orcid.org/0009-0001-2850-0432
Daejin ChoiCollege of Artificial Intelligence, Ewha Womans University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-5070-360X
Jae Hyun KimSchool of Pharmacy and Institute of New Drug Development, Jeonbuk National University, Jeonju, Republic of Korea.ORCID https://orcid.org/0000-0002-8609-7135
Sandy Jeong RhieGraduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-2554-3370
Yoshihiro NoguchiLaboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0000-0002-9110-9604
Myeong Gyu KimGraduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-5593-7672

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCausality assessment is central to pharmacovigilance but remains resource-intensive and subjective. The applicability of large language models (LLMs) to formal World Health Organization-Uppsala Monitoring Centre (WHO-UMC) drug-adverse event causality assessment has not been well established.

objectiveThis study aims to evaluate the performance of LLMs in WHO-UMC causality assessment.

methodsA curated set of 55 cases derived from the US Food and Drug Administration Adverse Event Reporting System, comprising 337 drug-level assessments, was constructed. Cases involving 2 to 11 suspected drugs were stratified by drug count, and 5 cases were sampled from each stratum. To ensure representation of rare but clinically important categories, 5 additional cases containing at least 1 "Certain" drug-adverse event pair were included. Case data were reorganized into a standardized semistructured format that preserved key elements required for WHO-UMC causality assessment. Domain experts conducted a pilot evaluation to align interpretation criteria prior to independently assessing the final dataset, yielding an interexpert agreement (Fleiss κ) of 0.762 across 337 drug-level assessments. Multiple prompting strategies, including standard prompting, chain-of-thought (CoT), CoT with self-consistency, few-shot, reasoning and acting, and tree-of-thought prompting, were applied across multiple LLMs, including GPT-5.4 and its mini variant and Gemini 2.5 Flash and Pro, via their respective application programming interfaces. Agreement with expert assessments was quantified using Cohen κ, weighted κ, and accuracy metrics. Internal consistency across repeated inferences was evaluated using Fleiss κ.

resultsPerformance varied across models and prompting strategies. Cohen κ ranged from 0.368 to 0.641, weighted κ ranged from 0.641 to 0.821, accuracy ranged from 0.583 to 0.804, and balanced accuracy ranged from 0.513 to 0.735. Fleiss κ ranged from 0.730 to 0.915, corresponding to substantial to almost perfect agreement. The highest Cohen κ was observed for Gemini 2.5 Flash with CoT prompting (0.641). Gemini 2.5 Flash with CoT-self-consistency prompting showed a Cohen κ of 0.640 and achieved the highest observed point estimates for weighted κ (0.821), accuracy (0.804), and Fleiss κ (0.915), although the gains over other prompting strategies were modest. Category-level performance for this model showed higher performance for "Certain" (F

conclusionsLLMs demonstrated moderate to substantial agreement in WHO-UMC causality assessment, indicating meaningful but still limited performance relative to expert judgment. Although LLMs are not suitable for independent decision-making, they may serve as supportive tools in pharmacovigilance workflows, particularly for preliminary case triage. Further studies using larger and more diverse datasets and evaluating performance on raw narrative reports are warranted.

Indexed as

Adverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsUnited States Food and Drug AdministrationWorld Health OrganizationCausalityHumansLarge Language ModelsPharmacovigilanceUnited StatesGeminigenerative pretrained transformerGPTlarge language modelsprompt engineeringWHO-UMC causality assessmentWorld Health Organization–Uppsala Monitoring Centre causality assessment

Identifiers

PMID42418253
PMCPMC13392529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.